Compare AU
Compare IXI vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the iShares Global Consumer Staples ETF (IXI) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
IXI | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 39 | 76 |
Median incremental investment | $993.50 | $651.42 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,697.56 | $1,290.00 |
Average age group | > 35 | > 35 |
Key Summary
IXI | CURE | |
|---|---|---|
Strategy | IXI.AX was created on 2006-09-12 by iShares. The fund's investment portfolio concentrates primarily on consumer staples equity. The fund aims to provide investors with the performance of the S&P Global 1200 Consumer Staples Sector Index, before fees and expenses. The index is designed to measure the performance of global consumer staples companies and may include large-, mid- or smallcapitalisation stocks. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | ISHARES GLOBAL CONSUMER STAPLES ET (99.99 %) USD CASH (0.01 %) AUD CASH (0.00 %) | Exact Sciences Corp (3.25 %) Alnylam Pharmaceuticals Inc (3.03 %) Neurocrine Biosciences Inc (2.99 %) |
Top 3 industries | Other (99.92 %) Communication Services (0.08 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (62.00 %) United Kingdom of Great Britain and Northern Ireland (12.09 %) Japan (5.56 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.4 % | 0.45 % |
Key Summary
IXI | CURE | |
|---|---|---|
Issuer | iShares | Global X |
Tracking index | S&P Global 1200 / Consumer Staples -SEC | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.4 % | 0.45 % |
Price | $102.60 | $43.00 |
Size | $138.661 million | $28.877 million |
10Y return | 70.72 % | N/A |
Annual distribution yield (5Y) | 2.23 % | 4.24 % |
Market | ASX | ASX |
First listed date | 11/03/2009 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
IXI | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 39 | 76 |
Median incremental investment | $993.50 | $651.42 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,697.56 | $1,290.00 |
Average age group | > 35 | > 35 |
Pros and Cons
IXI | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
IXI | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |